BRIDGEWATER, N.J., March 24, 2016 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces today the launch of Levetiracetam Immediate-Release Tablets (250mg, 500mg, 750mg, 1000mg), a bioequivalent generic version of Keppra®[1] in the US market.
Ajanta Pharma’s launch of Levetiracetam Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. To date, the United States Food & Drug Administration (FDA) has granted Ajanta Pharma eight ANDA final approvals and two tentative approvals. An additional 16 ANDAs are pending approval from the FDA.
About Ajanta Pharma
Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing quality, pharmaceuticals across 35 countries. Its mission is to serve global healthcare needs through empathy, innovation and technology.
For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.
[1] Keppra is a registered trademark of UCB Pharma
Photo - http://photos.prnewswire.com/prnh/20160324/347728
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-levetiracetam-tablets-300241012.html
SOURCE Ajanta Pharma USA Inc.
